CareDx: Molly Martell, 415-728-6307, firstname.lastname@example.org
HeartBrothers: Pat Sullivan, 508-579-5878, email@example.com
The HeartBrothers Foundation Presented With Support from CareDx to expand Heart Transplant Education and Patient Support
FRAMINGHAM, Mass., May 25, 2016 – The HeartBrothers Foundation, a 501c(3) organization headquartered in Framingham, Mass., announced today it has received support from CareDx, Inc. (Nasdaq: CDNA), a global molecular diagnostics company focused on the development and commercialization of clinically differentiated, high value diagnostic solutions for transplant patients.
The HeartBrothers Foundation, now 18 months in operation, is pleased to have CareDx on its growing list of corporate donors as it continues its mission of bringing resources together to help heart failure patients and their loved ones effectively deal with the challenges of living with heart failure. The funds from CareDx will be used to develop the Foundation’s peer-to-peer support initiatives, specifically the expansion of its Team HeartBrothers Program, a grassroots volunteer group of heart failure survivors who visit newly hospitalized patients and loved ones to provide support and assistance; its dedication to spreading organ donation awareness; and its first-hand education on living with heart failure and life post-organ transplant.
“We are pleased to receive continued support from this and other organizations,” said Patrick Sullivan, one of the Foundation’s co-founders and a heart transplant survivor. “Like us, CareDx is working to ease the lives of transplant patients and improve their overall post-transplant experience and health.”
“We are very proud of our support to the HeartBrothers Foundation since its inception,” says Peter Maag, President and CEO of CareDx. “The Team HeartBrothers Program is an important resource and expanding its reach will surely benefit more patients.”
About The HeartBrothers Foundation
The HeartBrothers Foundation is a 501(c)3 non-profit foundation dedicated to helping patients and families navigate the complicated world of Heart Failure (HF), Ventricular Assist Devices (VAD’s) and Heart Transplantation. Its mission is to fill financial gaps for patients by offering essential support through medical insurance assistance programs, informative stress-coping resources and connections to the global heart failure community. The HeartBrothers Foundation was founded in 2014 by heart transplant survivors Bob Romer and Pat Sullivan, who together have more than three decades of experience dealing with the often-fatal condition of heart failure. For more information, visit www.heartbrothers.org.
CareDx, Inc., headquartered in Brisbane, California, is a global molecular diagnostics company focused on the discovery, development, and commercialization of clinically differentiated, high-value diagnostic solutions for transplant patients. The company markets AlloMap®, a gene expression test that aids clinicians in identifying heart transplant recipients with stable graft function who have a low probability of moderate/severe acute cellular rejection. For more information, please visit: www.caredx.com.